See more : Incredible Industries Limited (INCREDIBLE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Morphic Holding, Inc. (MORF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morphic Holding, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nintendo Co., Ltd. (0R1E.L) Income Statement Analysis – Financial Results
- Shenzhen Yanmade Technology Inc. (688312.SS) Income Statement Analysis – Financial Results
- Styrenix Performance Materials Limited (STYRENIX.BO) Income Statement Analysis – Financial Results
- Corona Corporation (5909.T) Income Statement Analysis – Financial Results
- MediciNova, Inc. (MNOV) Income Statement Analysis – Financial Results
Morphic Holding, Inc. (MORF)
About Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 521.00K | 70.81M | 19.79M | 44.95M | 16.98M | 3.36M | 0.00 |
| Cost of Revenue | 1.09M | 1.00M | 1.03M | 73.63M | 53.73M | 22.63M | 434.00K |
| Gross Profit | -570.00K | 69.80M | 18.76M | -28.69M | -36.76M | -19.27M | -434.00K |
| Gross Profit Ratio | -109.40% | 98.58% | 94.80% | -63.82% | -216.50% | -573.94% | 0.00% |
| Research & Development | 140.38M | 102.06M | 87.79M | 73.63M | 53.73M | 22.63M | 14.10M |
| General & Administrative | 38.82M | 32.14M | 27.81M | 18.50M | 10.23M | 5.36M | 2.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 32.14M | 27.81M | 18.50M | 10.23M | 5.36M | 2.83M |
| Other Expenses | 2.00K | -145.00K | -8.00K | -19.00K | -94.00K | -74.00K | -5.00K |
| Operating Expenses | 179.21M | 134.20M | 115.60M | 92.13M | 63.97M | 27.99M | 16.93M |
| Cost & Expenses | 179.21M | 134.20M | 115.60M | 92.13M | 63.97M | 27.99M | 16.93M |
| Interest Income | 26.97M | 4.57M | 272.00K | 1.63M | 4.67M | 871.00K | 14.00K |
| Interest Expense | 0.00 | 4.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.09M | 1.00M | 1.03M | 1.13M | 821.00K | 539.00K | 434.00K |
| EBITDA | -177.60M | -62.39M | -94.78M | -46.05M | -46.17M | -24.09M | -16.50M |
| EBITDA Ratio | -34,087.33% | -89.53% | -484.02% | -104.97% | -271.94% | -717.36% | 0.00% |
| Operating Income | -178.69M | -63.40M | -95.81M | -47.18M | -46.99M | -24.63M | -16.93M |
| Operating Income Ratio | -34,296.74% | -89.53% | -484.02% | -104.97% | -276.77% | -733.41% | 0.00% |
| Total Other Income/Expenses | 26.97M | 4.42M | 264.00K | 1.61M | 4.57M | 797.00K | 9.00K |
| Income Before Tax | -151.72M | -58.97M | -95.54M | -45.57M | -42.42M | -23.83M | -16.92M |
| Income Before Tax Ratio | -29,119.96% | -83.29% | -482.68% | -101.39% | -249.84% | -709.68% | 0.00% |
| Income Tax Expense | 380.00K | 67.00K | -1.30M | -570.00K | 912.00K | 797.00K | -14.00K |
| Net Income | -152.10M | -59.04M | -94.24M | -45.00M | -43.33M | -23.83M | -16.92M |
| Net Income Ratio | -29,192.90% | -83.38% | -476.10% | -100.12% | -255.22% | -709.68% | 0.00% |
| EPS | -3.59 | -1.55 | -2.63 | -1.47 | -1.44 | -1.04 | -0.74 |
| EPS Diluted | -3.59 | -1.55 | -2.63 | -1.47 | -1.44 | -1.04 | -0.74 |
| Weighted Avg Shares Out | 42.39M | 38.11M | 35.80M | 30.59M | 30.15M | 22.89M | 22.89M |
| Weighted Avg Shares Out (Dil) | 42.39M | 38.11M | 35.80M | 30.59M | 30.19M | 22.89M | 22.89M |
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!
Source: https://incomestatements.info
Category: Stock Reports